

## Multi-omic network analysis identifies dysregulated neurobiological pathways in opioid addiction

Kyle A. Sullivan<sup>1</sup>, David Kainer<sup>1</sup>, Matthew Lane<sup>2</sup>, Mikaela Cashman<sup>1,3</sup>, J. Izaak Miller<sup>1</sup>, Michael R. Garvin<sup>1</sup>, Alice Townsend<sup>2</sup>, Bryan C. Quach<sup>4</sup>, Caryn Willis<sup>4</sup>, Peter Kruse<sup>2</sup>, Nathan C. Gaddis<sup>4</sup>, Ravi Mathur<sup>4</sup>, Olivia Corradin<sup>5</sup>, Brion S. Maher<sup>6</sup>, Peter C. Scacheri<sup>7</sup>, Sandra Sanchez-Roige<sup>8,9</sup>, Abraham A. Palmer<sup>8,10</sup>, Vanessa Troiani<sup>11</sup>, Elissa J. Chesler<sup>12</sup>, Rachel L. Kember<sup>13,14</sup>, Henry R. Kranzler<sup>13,14</sup>, Amy C. Justice<sup>15,16,17</sup>, Ke Xu<sup>15,18</sup>, Bradley E. Aouizerat<sup>19</sup>, VA Million Veteran Program, Dana B. Hancock<sup>4\*</sup>, Eric O. Johnson<sup>4,20\*</sup>, and Daniel A. Jacobson<sup>1\*</sup>

<sup>1</sup>Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, TN

<sup>2</sup>The Bredesen Center for Interdisciplinary Research and Graduate Education, University of Tennessee-Knoxville, Knoxville, TN

<sup>3</sup>Environmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory Berkeley, CA

<sup>4</sup>RTI International, Research Triangle Park, NC

<sup>5</sup>Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA

<sup>6</sup>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

<sup>7</sup>Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH

<sup>8</sup>Department of Psychiatry, University of California San Diego, La Jolla, CA

<sup>9</sup>Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN

<sup>10</sup>Institute for Genomic Medicine, University of California San Diego, La Jolla, CA

<sup>11</sup>Geisinger College of Health Sciences, Scranton, PA

<sup>12</sup>The Jackson Laboratory, Bar Harbor, ME

<sup>13</sup>Mental Illness Research, Education and Clinical Center, Crescenz Veterans Affairs Medical Center, Philadelphia, PA

<sup>14</sup>Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

<sup>15</sup>Veterans Affairs Connecticut Healthcare System, West Haven, CT

<sup>16</sup>Department of Internal Medicine, Yale University School of Medicine, New Haven, CT

<sup>17</sup>Department of Health Policy and Management, Yale School of Public Health, New Haven, CT

<sup>18</sup>Department of Psychiatry, Yale School of Medicine, New Haven, CT

<sup>19</sup>Bluestone Center for Clinical Research, College of Dentistry, New York University, New York, NY

<sup>20</sup>Fellow Program, RTI International, Research Triangle Park, NC

\*Correspondence: [jacobsonda@ornl.gov](mailto:jacobsonda@ornl.gov), [ejohnson@rti.org](mailto:ejohnson@rti.org), [dhancock@rti.org](mailto:dhancock@rti.org)

This manuscript has been authored by UT-Battelle, LLC under Contract No. DE-AC05-00OR22725 with the U.S. Department of Energy. The United States Government retains and the publisher, by accepting the article for publication, acknowledges that the United States Government retains a non-exclusive, paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes. The Department of Energy will provide public access to these results of federally sponsored research in accordance with the DOE Public Access Plan (<http://energy.gov/downloads/doe-public-access-plan>).

## 1 **Abstract**

2           Opioid addiction constitutes a public health crisis in the United States and opioids cause  
3 the most drug overdose deaths in Americans. Yet, opioid addiction treatments have limited  
4 efficacy. To help address this problem, we used network-based machine learning techniques to  
5 integrate results from genome-wide association studies (GWAS) of opioid use disorder and  
6 problematic prescription opioid misuse with transcriptomic, proteomic, and epigenetic data from  
7 the dorsolateral prefrontal cortex (dlPFC) in opioid overdose victims. We identified 211 highly  
8 interrelated genes identified by GWAS or dysregulation in the dlPFC of individuals with opioid  
9 overdose victims that implicated the Akt, BDNF, and ERK pathways, identifying 414 drugs  
10 targeting 48 of these opioid addiction-associated genes. This included drugs used to treat other  
11 substance use disorders and antidepressant drugs. Our synthesis of multi-omics using a systems  
12 biology approach revealed key gene targets that could contribute to drug repurposing, genetics-  
13 informed addiction treatment, and future discovery.

## 14 **Introduction**

15  
16 Worldwide, over 60 million people misuse opioid drugs resulting in an estimated 12.9  
17 million healthy years of life lost (disability-adjusted life years)<sup>1</sup>. These drugs include both opioids  
18 prescribed for pain relief (*e.g.*, hydrocodone, oxycodone) and illicit opioids (*e.g.*, heroin, fentanyl).  
19 In the United States, over 9 million people in the housed population (which excludes homeless and  
20 institutionalized individuals) aged 12 and older were estimated to misuse opioids in 2020<sup>2</sup>, and  
21 over 80,000 people died of an opioid-related overdose in 2021 – continuing a decades long  
22 epidemic of opioid misuse and overdose deaths<sup>3,4</sup>. Yet only 1.27 million people in the United States  
23 receive medication-assisted treatment with one of the three medications approved to treat opioid  
24 use disorder (OUD)<sup>5</sup>: methadone (opioid agonist), buprenorphine (opioid agonist/antagonist), or  
25 naltrexone (opioid antagonist). Substance use disorders are widely accepted to involve genetic and  
26 experiential influences on brain circuits related to motivated behavior. Thus, there is a great need  
27 for a better understanding of the neurobiology of opioid addiction and the identification of novel  
28 targets for drug development.

29 Several recent genome-wide association studies (GWAS)<sup>6–10</sup> have identified genetic  
30 variants and genes associated with increased risk of opioid addiction phenotypes. Other studies  
31 have identified gene dysregulation in postmortem human brains associated with opioid overdose  
32 deaths<sup>11–15</sup>. Up to 18 genome-wide significant loci have been reported across the most recent  
33 GWASs for OUD or prescription opioid misuse, with replicated associations being observed for  
34 *OPRM1*<sup>7–10</sup>, *FURIN*<sup>7–9</sup>, the *SCAI/PPP6C/RABEK* cluster<sup>7–9</sup>, and *PTPRF*<sup>6,9</sup>. In parallel, four  
35 RNA-seq studies identified hundreds of potentially differentially expressed genes in human  
36 postmortem dorsolateral prefrontal cortex (dlPFC), which were enriched for a variety of biological  
37 functions (*e.g.*, extracellular matrix, angiogenic cytokines, and MAPK signaling). These studies

38 did not include replication, but we found that 11 genes replicate across these cohorts for the dlPFC  
39 (Bonferroni corrected  $p < 0.05$ ), and a meta-analysis<sup>16</sup> of these cohorts identified up to 335  
40 dysregulated genes in the dlPFC (Benjamini-Hochberg FDR p-value  $< 0.05$ ).

41 Although these recent findings provide important clues to the biology underlying opioid  
42 addiction, these genes do not function in isolation. Additional insights may be gained through a  
43 systems biology approach that identifies affected functional networks from disease-associated  
44 genes<sup>17</sup>. Here, we used results from existing studies to identify 404 opioid addiction-related genes  
45 from which we removed potential false positives with the recently developed Gene set Refinement  
46 through Interacting Networks (GRIN<sup>17</sup>) software. GRIN enabled us to identify a tightly integrated  
47 set of 211 genes that mapped to multiple neurobiological pathways. Fifty of the 211 genes  
48 implicated in opioid addiction signaling or other substance use disorders were tightly  
49 interconnected using cross validation and a concise shortest-paths network between pairs of genes.  
50 We created a conceptual model of the network mapped to BDNF and MAPK signaling pathways  
51 and synaptic signaling processes, among others, showing widespread downregulation of these  
52 genes in opioid addiction. Moreover, multiple genes appear to be promising targets for novel drug  
53 repurposing for treating OUD based on their role as gene targets for drugs used to treat other  
54 substance use disorders. Our results demonstrate the utility of integrating multiple omics in  
55 systems biology approaches that leverage machine learning techniques, discovering novel  
56 biological relationships that underlie opioid addiction.

## 57 **Results**

58 *Meta-analysis of opioid addiction omics data sets combined with network biology identifies 211*  
59 *highly interrelated genes.*

60 We first identified opioid addiction-associated genes from multiple omics data sets using  
61 the postmortem dlPFC and GWAS SNP-nearest gene assignment (**Figure 1**). Using consistent  
62 significance thresholds within each omics data set across studies (Online Methods), we identified  
63 404 unique opioid addiction genes from the following omics data types: 256 genes associated with  
64 H3K27ac ChIP-seq peaks<sup>11</sup>, 13 DNA methylation-associated genes<sup>15</sup>, 33 GWAS-associated  
65 genes<sup>6-10</sup>, 3 protein-coding genes associated with differentially abundant proteins from LC/MS  
66 proteomics<sup>12</sup>, and 104 differentially expressed genes from RNA-seq<sup>11-14</sup> (**Supplementary Tables**  
67 **1-7**).

68 Of the 404 opioid addiction-related genes, we sought to identify those that are highly  
69 interconnected in biological networks using multiple lines of experimental evidence from data  
70 independent of the opioid omics data sets. Using GRIN<sup>17</sup>, we removed potential false positive  
71 genes based on network connectivity within a multiplex network consisting of 10 layers of  
72 biological evidence. GRIN uses the algorithm Random Walk with Restart (RWR) to identify  
73 tightly interconnected genes and removes those that do not depart from the gene ranks of a null  
74 distribution. GRIN identified 211 highly interrelated opioid addiction genes across omics data  
75 types (**Figure 2A, Supplementary Tables 8-9**).

76 Before GRIN filtering, the 404 unfiltered genes were significantly enriched for 103 Gene  
77 Ontology (GO<sup>18</sup>) Biological Process terms. The 211 genes that remained after GRIN filtering were  
78 enriched for 293 terms, including 96 of the same enriched biological processes as were in the  
79 unfiltered gene set prior to the application of GRIN (**Figure 2B, Supplementary Tables 10-11**).  
80 In contrast, the 193 genes removed by GRIN were not significantly enriched for any GO Biological  
81 Process terms, clearly differentiating them from the 211 retained genes. Thus, the subset of 211

82 genes retained by GRIN were highly biologically interrelated based on interconnectivity within  
83 the biological multiplex network and better mapping to known biological processes.

84  
85 *A subset of multi-omic genes previously implicated in opioid signaling and substance use disorders*  
86 *are highly interconnected in biological networks.*

87 Of the 211 genes retained by GRIN, we focused on a subset of 50 unique, high-confidence  
88 genes (**Supplementary Table 12**) that were either implicated across 2 or more studies or  
89 previously implicated in opioid signaling or in other substance use disorders (Online Methods).  
90 Gene set enrichment analyses indicated that, among other functions, these high confidence genes  
91 were enriched for the BDNF and MAPK signaling pathways and synaptic signaling processes  
92 (**Supplementary Table 13**).

93 Using shortest paths network traversal to identify the fewest connections between each pair  
94 of the 50 high-confidence opioid addiction genes, we found that 43 were directly connected to at  
95 least one other gene in the set (**Figure 3A, Supplementary Table 14**). Moreover, the other 7 high  
96 confidence genes were only two connections away from at least one of the other 50 high confidence  
97 genes (**Figure 3A, Supplementary Table 14**). Only 127 additional network-connecting genes (not  
98 high-confidence opioid addiction genes) were necessary to link pairs of genes that could be  
99 connected as direct neighbors or by a shared neighboring gene. Furthermore, 3 of the 127 network-  
100 connecting genes (*SERPINB1*, *SORCSI*, and *SORLI*) were members of the original 211 GRIN-  
101 retained gene set (**Figure 3A, Supplementary Table 15**).

102 Next, we explored the interconnectivity of the 50 high-confidence opioid addiction genes  
103 using RWR. We employed a cross-validation approach in which a subset of the opioid addiction  
104 genes were used as starting points to explore the biological networks with RWR, and the remaining

105 genes were ranked against the rest of the genes in the biological network based on how often the  
106 gene was visited by RWR. Using this cross-validation approach, we observed a high area under  
107 receiver-operator characteristic curve (AUROC) value (AUROC = 0.94; **Figure 3B**). The high  
108 AUROC value indicated that, during cross validation, genes that were used to explore the networks  
109 frequently visited the genes that were left out of the gene set. Combined with our small shortest  
110 paths network, these results confirmed that these 50 genes were highly interconnected in our  
111 biological multiplex network.

112

113 *Conceptual model of biological pathways underlying opioid addiction multi-omic genes.*

114 After integrating the 211 multi-omic opioid addiction genes using our network approaches,  
115 we identified multiple pathways unifying these genes. From this investigation, we developed a  
116 conceptual model consisting of 45 opioid addiction genes and 26 other genes, proteins, or  
117 molecules in associated pathways (**Figure 4**). Multiple genes in the BDNF pathway were  
118 implicated, including *BDNF*, whose expression was downregulated and its receptor *NTRK2*  
119 (TrkB), which exhibited decreased H3K27ac ChIP-seq peaks in opioid samples (**Figure 4**). A  
120 number of genes were also implicated downstream of the BDNF pathway, including *RASGRF1*,  
121 *PIK3R1* and *GSK3B* in the PI3K/Akt pathway. The ERK MAPK pathway was also strongly  
122 implicated, as the  $\mu$ -opioid receptor (*OPRM1*), GABA<sub>B</sub> receptor (*GABBR2*), and *PDE4B* were  
123 implicated upstream of ERK along with multiple ERK phosphatases (*DUSP2*, *DUSP4*, *DUSP6*,  
124 *DUSP10*, *PPP6C*). Downstream of the ERK and Akt pathways, CREB (*CREB5*) and a number of  
125 its target genes were also implicated in opioid addiction, including several immediate early genes  
126 (*ARC*, *EGR1*, *EGR2*, *EGR4*, *FOS*, *MYC*, *NPAS4*) and genes involved in synaptic plasticity (*BDNF*,

127 *NTNI*)<sup>19</sup>. Additionally, the transcription factor *RORA* was predicted to activate the transcription of  
128 the multi-omic opioid addiction genes: astrotactin-2 (*ASTN2*) and galectin-3 (*LGALS3*)<sup>20</sup>.

129 In addition to the BDNF, ERK, and Akt signaling pathways, multiple ion channel subunits  
130 and cell adhesion molecules that may influence neurotransmission were identified by multi-omic  
131 integration. Filamin A (*FLNA*) binds OPRM1 <sup>21</sup>, FURIN <sup>22</sup>, and the GRIK3 subunit of the kainate  
132 glutamatergic receptor<sup>23</sup> (**Figure 4**). Moreover, the astrocytic glutamate transporter EAAT2 gene  
133 (*SLCIA2*) was implicated by hypoacetylated ChIP-seq. Multiple ionotropic GABA receptor  
134 subunit genes (*GABRE*, *GABRG3*), a voltage-gated calcium channel subunit gene (*CACNB2*), and  
135 multiple ATP or Ca<sup>2+</sup>-activated K<sup>+</sup> channel subunit genes (*ABCC8*, *KCNMA1*, *KCNN1*) were  
136 identified by ChIP-seq, GWAS, or RNA-seq. Genes encoding cell adhesion molecules (*NCAMI*  
137 <sup>24</sup>, *NRXN3* <sup>25</sup>) that can modulate synaptic connectivity were also implicated in our multi-omic  
138 opioid addiction gene set, and microglial inflammation was implicated by the galectin-3 gene  
139 (*LGALS3* <sup>26</sup>). Notably, most genes exhibited decreased gene expression, hypoacetylated H3K27ac  
140 peaks, or increased DNA methylation, except for increased *GABRE* and *MYC* gene expression and  
141 increased protein abundance of *LGALS3*.

142

143 *Putative pharmacological target genes in opioid addiction.*

144 After identifying biological pathways and highly interrelated genes by integrating the  
145 multi-omic opioid addiction data sets, we identified genes whose protein products are candidates  
146 for pharmacological manipulation and potential drug repurposing. We constructed a network of  
147 48 druggable opioid addiction genes and 414 approved or experimental drugs known to target the  
148 products of these genes (**Figure 5, Supplementary Table 16**). Currently approved treatments for  
149 opioid use disorder (OUD) or overdose that target the mu-opioid receptor (encoded by *OPRM1*)



150 are included in the network (buprenorphine, methadone, nalmefene, naloxone, and naltrexone).  
151 Naltrexone is also approved for treating alcohol use disorder (AUD)<sup>27</sup>, and other approved or  
152 investigational AUD treatments<sup>27</sup> were also present in the network, such as acamprosate<sup>27</sup> (*GABRE*  
153 and *GABRG3*), baclofen<sup>27</sup> (*GABBR2*), ibudilast<sup>28</sup> (*PDE4B*), and topiramate<sup>27,29</sup> (*CACNB2*, *GRIK3*,  
154 and *SCN8A*; **Figure 5, Supplementary Table 16**).

155 In addition to drugs approved for treating substance use disorders, multiple drugs in the  
156 network targeting opioid addiction multi-omic genes are currently approved for psychiatric  
157 treatment or are known to have psychiatric effects. This includes the drug spironolactone (targeting  
158 *CACNB2* and *PGR*), which has recently been investigated for treating AUD<sup>30</sup>, and multiple  
159 approved antidepressants<sup>31,32</sup> such as amitriptyline (*ADRAID*, *NTRK2*, *OPRM1*), amoxapine  
160 (*ADRAID*, *GABRE*, *GABRG3*), and esketamine (*BDNF*, *NTRK2*). The network also includes  
161 known drugs of abuse (e.g., opioids, ethanol, promethazine) and widely prescribed drugs with  
162 potential for misuse, including antipsychotics (e.g., aripiprazole<sup>33,34</sup> (*OPRM1*), dosulepin<sup>35</sup>  
163 (*ADRAID*), olanzapine<sup>33</sup> (*GABRG3*), pipamperone<sup>33</sup> (*ADRAID*), quetiapine<sup>33,36</sup> (*ADRAID*) and  
164 benzodiazepines (e.g., alprazolam<sup>37</sup>, lorazepam<sup>38</sup>, temazepam<sup>38</sup> that all target *GABRE* and  
165 *GABRG3*). A number of opioids are also present in the drug-gene target network based on their  
166 characterized effects on *OPRM1*.

167 Furthermore, multiple ionotropic and metabotropic ion channel and receptor subunits  
168 (*ADRAID*, *CACNB2*, *GABBR2*, *GABRE*, *GABRG2*, *GRIK3*, *KCNE4*, *KCNMA1*, *KCNS3*, *NTRK2*,  
169 *OPRM1*, *SCN8A*) that were identified by multi-omic integration are known targets of approved  
170 drugs. Many drugs (“Other Drugs”, **Figure 5**) targeted 2 or more of the multi-omic opioid  
171 addiction genes that have not been investigated for psychiatric effects. For example, 9 genes  
172 (*DAPK1*, *GSK3B*, *HIPK3*, *MARK1*, *NTRK2*, *PAK3*, *PLK4*, *STK17B*, and *STK24*) were targeted by

173 fostamatinib, indicating its potential to affect many opioid addiction genes simultaneously.  
174 Furthermore, we identified antagonists and agonists for most of the gene targets present in the  
175 conceptual model in **Figure 4** that were druggable, except for *FURIN* (only inhibitors), *GABBR2*  
176 (only agonists), *LGALS3* (unknown action), *SLCIA2* (substrate or inhibitors), and *SST* (only  
177 substrates). Thus, many of the genes in the biological pathways identified by our multi-omic  
178 integration are druggable targets and are novel candidates for drug repurposing studies.

## 179 **Discussion**

180 In the present study, we integrated multi-omic datasets using a systems biology approach  
181 to identify biological pathways and drug targets underlying opioid addiction. Importantly, by  
182 integrating genome-wide association studies and omics derived from the dlPFC of individuals who  
183 died from an opioid overdose, we identified distinct biological pathways implicated in this brain  
184 region, which is associated with opioid craving<sup>39-41</sup>, such as the Akt and BDNF signaling  
185 pathways, which were not identified in the original contributing studies. Drug-gene target network  
186 integration identified candidate drugs targeting gene products implicated in opioid addiction  
187 omics, as well as putative gene targets for experimental follow up. These efforts may inform the  
188 development of therapeutic interventions for opioid addiction.

189 After identifying GWAS and omics-derived genes using consistent thresholds across  
190 opioid addiction studies, we used GRIN<sup>17</sup> as a means of integrating these multi-omic data by  
191 identifying the most interrelated genes based on biological network connectivity. We used our  
192 previous validated multiplex network containing a dlPFC-derived predictive expression network  
193 in order to remove false positive genes from our gene set. Moreover, the dlPFC-specific network  
194 layers were congruent with the tissue of all transcriptomic and epigenetic data sets examined.  
195 Importantly, the 211 genes retained by GRIN were enriched for more GO Biological Processes

196 than the 404 genes not filtered by GRIN. From the 211 genes, we identified a subset of 50 that  
197 were either previously implicated in the risk for substance use disorders, in opioid receptor  
198 signaling, or by multiple opioid addiction omics. Based on the high AUROC value from our  
199 random walk with restart cross-validation approach and the fact that only 127 genes were needed  
200 to connect opioid addiction genes in a shortest paths network, we concluded that these 50 genes  
201 were highly interconnected in our multiplex network and therefore part of the same biological  
202 pathways. Notably, while some of these genes have previously been implicated in rodent models  
203 of opioid addiction (*e.g.*, *FOS*<sup>42-44</sup>, *MYC*<sup>45,46</sup>) or opioid receptor signaling (*NTN1*<sup>47</sup>, *RTP4*<sup>48,49</sup>),  
204 many of the other genes are not well-characterized in relation to opioid addiction or from human  
205 postmortem brain tissue.

206 Gene set enrichment analysis revealed a strong enrichment for the BDNF, ERK, and  
207 Akt/PI3K pathways from our opioid addiction genes. Notably, the study describing the LC/MS  
208 proteomics data set and two RNA-seq data sets previously implicated the p38 and ERK MAPK  
209 pathways<sup>11,12</sup>. Here, we confirm this finding and expand the implication of the ERK MAPK  
210 pathway beyond the genes identified in prior studies. Animal models have shown increased ERK  
211 phosphorylation in the hippocampus<sup>50</sup> and of the ERK scaffold protein PEA-15<sup>51</sup>. Decreased  
212 BDNF and associated epigenetic alterations have also been observed in the ventral tegmental area  
213 of postmortem tissue from human heroin addicts<sup>52</sup>. Moreover, the Akt/PI3K pathway has been  
214 implicated in differential gene expression from whole blood of subjects diagnosed with opioid use  
215 disorder<sup>53</sup>. However, to our knowledge this is the first study from the dlPFC in which multiple  
216 genes in the BDNF (*BDNF*, *NTRK2*) and Akt pathways (*GSK3B*, *PIK3R1*, *RASGRF1*) were  
217 implicated by opioid-induced transcriptomic and epigenetic alterations.

218 We also note that many of the 45 genes in our dlPFC opioid addiction conceptual model  
219 affect synaptic plasticity or neuronal signaling, and were largely associated with H3K27  
220 hypoacetylation and/or decreased gene expression. Both excitatory receptor subunits (*CACNB2*,  
221 *GRIK3*) and inhibitory receptor subunits (*ABCC8*, *GABBR2*, *GABRE*, *GABRG3*, *KCNMA1*,  
222 *KCNN1*, *OPRM1*) were implicated in opioid addiction, and all except the *GABRE* subunit were  
223 associated with decreased expression or less active chromatin. Moreover, the EAAT2 glutamate  
224 transporter (*SLCIA2*) was implicated by H3K27 hypoacetylation, an astrocytic transporter  
225 responsible for removing glutamate from the synaptic cleft that has been implicated in bipolar  
226 disorder and schizophrenia<sup>54</sup>. Coupled with a net decrease in immediate early gene expression  
227 (*ARC*, *EGR1*, *EGR2*, *EGR4*, *ETS1*, *ETV5*, *FOS*, *MYC*, *NPAS4*), genes whose expression is induced  
228 by cellular activation<sup>55-59</sup>, our opioid addiction genes are associated with decreased neuronal  
229 activity in the dlPFC. Future studies are warranted to determine if decreased gene expression and  
230 H3K27 hypoacetylation occur equally within excitatory and inhibitory neurons in the dlPFC.

231 Extending GWAS findings for opioid addiction, here we integrated omics data in the dlPFC  
232 based on its role in impulsivity and drug craving in opioid addiction<sup>39-41</sup>. This brain region has  
233 also been implicated in cigarette<sup>60</sup> and cocaine craving<sup>61</sup>. Moreover, randomized clinical trials  
234 have been conducted using transcranial magnetic stimulation over this brain region to reduce  
235 opioid craving<sup>62,63</sup>. Although omics from whole blood<sup>53,64,65</sup> and other brain regions, such as the  
236 midbrain<sup>66</sup>, nucleus accumbens<sup>13,67</sup>, orbitofrontal cortex<sup>68</sup>, and striatum<sup>69,70</sup> have been generated  
237 from individuals with a history of opioid addiction, focusing on GWAS and the dlPFC enabled us  
238 to examine genes from a brain region-specific perspective. Future studies should examine  
239 biological pathways involving NAc omics, particularly the extent to which these pathways overlap  
240 with dlPFC pathways. Furthermore, while the H3K27ac ChIP-seq data set integrated in this study

241 were derived from NeuN-positive neurons<sup>11</sup>, omics derived from other cell types (*e.g.*, astrocytes,  
242 microglia, oligodendrocytes) and neuronal subtypes can inform cell type-specific epigenomic,  
243 transcriptomic, and proteomic changes caused by opioid addiction.

244 After identifying opioid addiction genes in the dlPFC, we sought to identify which genes  
245 were known targets of previously approved medications using network visualization. Notably,  
246 approved treatments for opioid addiction<sup>71</sup> (buprenorphine, methadone, naltrexone) or overdose  
247 (nalmeferne and naloxone) were present within our drug-gene target network. In addition to these  
248 opioid-related treatments, drugs for which there is evidence of efficacy in treating alcohol use  
249 disorder were present in the network, including acamprosate<sup>27</sup>, baclofen<sup>27</sup>, ibudilast<sup>28</sup>, and  
250 topiramate. Of these, topiramate has limited evidence in clinical trials for its capacity to treat opioid  
251 addiction<sup>72</sup>, and has been extensively assessed for treating alcohol use disorder<sup>29</sup> and to a lesser  
252 extent cocaine<sup>73</sup> addiction. In addition to medications for treating substance use disorders, we  
253 identified multiple drugs that are widely prescribed for treating psychiatric disorders that may be  
254 comorbid with opioid addiction, such as depressive and anxiety disorders and schizophrenia.  
255 Studies are warranted to evaluate the extent to which these drugs could be used to treat opioid  
256 addiction. As many of the identified genes were associated with decreased gene expression or  
257 hypoacetylated H3K72ac ChIP-seq peaks, ascertaining whether these drugs increase (agonist) or  
258 decrease (antagonist) the downstream activity of these protein-coding genes is critical.  
259 Furthermore, an important question for drug repurposing efforts is how opioid addiction affects  
260 the expression of the genes identified in the dlPFC.

261 In considering drugs to be repurposed for treating addiction, weighing the potential risks  
262 associated with them is essential. A number of drugs in the network that are widely used in  
263 psychiatry, such as the benzodiazepines alprazolam<sup>37</sup> and lorazepam<sup>38</sup>, have the potential for

264 misuse; thus, any efforts to repurpose these drugs must consider their potential for adverse effects.  
265 Future work might also include using real world data to determine safety and whether there is  
266 evidence that the use of these medications is associated with decreased use of opioids.

267         There are limitations to the current study that are worth noting. Notably, the omics from  
268 the dlPFC included in the study are from bulk tissue, rather than individual cellular populations.  
269 As they become available, integrating single-cell transcriptomic and epigenetic datasets would  
270 give valuable insight into the neuronal and/or glial cell populations affected by opioid addiction in  
271 the prefrontal cortex. Adding single cell-specific context into networks (*e.g.*, including a  
272 glutamatergic neuron-specific predictive expression network) would provide additional cellular  
273 perspective into the relationships among the multi-omic genes, beyond a tissue-level perspective.  
274 Furthermore, gene dysregulation in the dlPFC was identified by comparing opioid overdose death  
275 cases to controls. Such differences in gene regulation may be attributable to a variety of causes  
276 (*e.g.*, chronic opioid exposure / addiction, genetic risks for opioid addiction, acute death from an  
277 opioid overdose, differences in diet, other drug use, or circadian disruption). It is likely that  
278 functional studies in model organisms will be needed to differentiate such causes. Finally, while  
279 we have included currently available genes implicated by GWAS and omics data, there are likely  
280 additional genes contributing to opioid addiction that have not yet been implicated due to these  
281 genes failing to reach statistical significance. Thus, as sample sizes continue to increase from  
282 opioid addiction GWAS and postmortem omics data from opioid overdose, there may be additional  
283 genes and pathways implicated within the dlPFC based on increased statistical power.

284         In summary, we used network biology techniques to integrate multiple opioid addiction  
285 omics data sets from a systems biology perspective. By identifying biological pathways  
286 dysregulated in the dlPFC following opioid addiction and druggable gene targets in these

287 pathways, we identified candidate medications that merit experimental follow up as potential  
288 treatments for opioid addiction.

## 289 **Online Methods**

290  
291 *Integrating opioid addiction multi-omic genes.*

292 Opioid addiction genes were integrated from the following types of previously published  
293 omics data sets involving postmortem dorsolateral prefrontal cortex (dlPFC) from control subjects  
294 and subjects who died of an opioid overdose: H3K27ac chromatin immunoprecipitation  
295 sequencing (ChIP-seq<sup>11</sup>), DNA methylation<sup>15</sup>, liquid chromatography-mass spectrometry  
296 (LC/MS<sup>12</sup>), and bulk RNA sequencing (RNA-seq<sup>11-14</sup>). We also included genes identified from  
297 opioid addiction genome-wide association studies (GWAS). Together, 404 unique genes present  
298 in the multiplex network were identified based on the following thresholding procedures.

299 Differential ChIP-seq peaks were derived from previous H3K27ac ChIP-seq obtained from  
300 prefrontal cortex samples of controls and subjects that died of opioid overdose (**Supplementary**  
301 **Table 1**)<sup>11</sup>. From 388 differentially acetylated H3K27ac ChIP-seq peaks based on a threshold of  
302 Bonferroni-corrected  $p < 1e^{-7}$ , peaks were re-mapped to genes using the “annotatePeak” function  
303 from the ChIPseeker R function<sup>74</sup> using hg19/GRCh37 coordinates and a 1kb window around the  
304 transcriptional start site to define the promoter region. This annotation was used in contrast to the  
305 GREAT<sup>75</sup> peak-to-gene annotation listed in the original publication<sup>11</sup>, as ChIP-seeker annotates  
306 the location of peaks (i.e. intronal, exonal, promoter, 5’UTR, 3’UTR, distal intergenic) and  
307 mapped peaks to genes that GREAT did not annotate. Reciprocally, if ChIPseeker did not map a  
308 peak to a gene, the GREAT peak-to-gene annotation was used. Together, these 388 H3K27ac  
309 ChIP-seq peaks mapped to 267 unique genes. Furthermore, we included the 5 genes (*ASTN2*,

310 *DUSP4*, *ENOX1*, *GABBR2*, *KCNMA1*) associated with variant enhancer loci lost in opioid  
311 overdose subjects using promoter-capture Hi-C that were statistically significant at FDR-corrected  
312  $p < 1e^{-6}$ , which added 2 unique genes to the H3K27ac ChIP-seq-associated gene list. Thirteen non-  
313 coding RNAs identified by ChIP-seq peaks were excluded from downstream analysis as they were  
314 not present in any layer of the multiplex network (**Supplementary Table 7**): *MIR30D*, *MIR3201*,  
315 *MIR3914-1*, *MIR4262*, *MIR4264*, *MIR4319*, *MIR4432*, *MIR4480*, *MIR4689*, *MIR4714*, *MIR4790*,  
316 *MIR488*, and *SNORA72*. In total, 256 unique genes were included among the H3K27ac ChIP-seq  
317 peaks.

318 Differentially methylated genes were identified using a previously published epigenome-  
319 wide association study of dlPFC tissue from subjects who died from opioid overdose using the  
320 Illumina Infinium MethylationEPIC BeadChip DNA methylation chip testing 850,000 CpG  
321 regions (**Supplementary Table 2**)<sup>15</sup>. Thirteen CpG sites were identified with adjusted  $p$ -values of  
322 0.4 (uncorrected  $p < 6e^{-6}$ ) and 3 CpG islands that were not mapped to genes (cg25084741,  
323 cg10759972, and cg26506680) were excluded. This yielded 13 unique genes identified by opioid-  
324 induced differential DNA methylation that were present in the multiplex network.

325 Genes were included from opioid use disorder<sup>8-10</sup> and prescription opioid misuse<sup>6</sup> GWAS  
326 based on SNP-nearest gene associations from SNPs with  $p < 5e^{-8}$ , resulting in 19 unique GWAS  
327 genes; an additional 15 unique genes were also identified from multi-trait analysis of GWAS  
328 (MTAG) using European opioid use disorder GWAS, alcohol use disorder, and cannabis use  
329 disorder summary statistics (**Supplementary Table 3**)<sup>7</sup>. These opioid addiction GWAS yielded  
330 34 unique genes, but one gene (*TMX2-CTNND1*) was not present in any layer of the multiplex  
331 and was excluded from downstream analyses (33 unique GWAS genes; **Supplementary Tables**  
332 **6-7**).



333 Differentially abundant proteins (**Supplementary Table 4**) were identified from a  
334 previously published LC/MS proteomics study from postmortem dlPFC from control and subjects  
335 diagnosed with opioid use disorder<sup>12</sup>. Three protein coding genes (*ATP5J2*, *LGALS3*, *TAF15*) were  
336 included based on a threshold of adjusted  $p$ -value  $< 0.05$  and absolute value of  $\log_2$  fold change  
337 (FC) greater than or equal to 1.5 ( $\log_2\text{FC} \leq -1.5$  or  $\log_2\text{FC} \geq 1.5$ ) which were included in  
338 downstream analyses.

339 Differentially expressed genes (DEGs; **Supplementary Table 5**) were identified from four  
340 RNA-seq studies derived from postmortem dlPFC of controls and subjects who died of opioid  
341 overdose or were diagnosed with opioid use disorder<sup>11-14</sup>. DEGs were included in downstream  
342 analyses based on thresholds of adjusted  $p$ -value  $< 0.05$  and  $|\log_2\text{FC}| \geq 0.5$ . Using these thresholds,  
343 we identified 106 unique genes identified in opioid addiction by RNA-seq and 103 genes present  
344 in the multiplex were included in downstream analyses (*AC018647.3*, *AL606753.2*, and *PARTICL*  
345 were excluded, **Supplementary Table 7**).

346 Multiple genes were implicated in opioid addiction by multiple lines of biological  
347 evidence. Four genes were identified across multiple omics data types: *DUSP4*, *DUSP6*, *ETV5*,  
348 and *PLA2GS*. Additionally, 60 ChIP-seq opioid addiction genes were identified by multiple  
349 H3K27ac ChIP-seq peaks, and *ARL4D* was identified as a DEG in two separate RNA-seq  
350 studies<sup>12,13</sup>. Furthermore, *FURIN*<sup>7-9</sup>, *NCAMI*<sup>7,8</sup>, *OPRM1*<sup>7-10</sup>, and the *SCAI/PPP6C/RABEPK*<sup>7-9</sup>  
351 gene cluster were identified across multiple opioid addiction GWAS.

352

353 *Multiplex network generation.*

354 Multiplex gene-gene networks were assembled from 10 layers from different types of  
355 biological evidence using GENCODE IDs for all genes. None of the multiplex network data

356 sources were from any of the opioid addiction omics data sets. The following network layers were  
357 used from HumanNet (version 2.0<sup>23</sup>): co-citation, co-essentiality, co-expression, pathway  
358 databases, gene neighborhood, interologs, and phylogenetic associations. A merged protein-  
359 protein interaction network was created by merging networks from HumanNet (version 2.0,  
360 literature curated and high-throughput assay-derived connections) and high-confidence  
361 interactions from STRING (version 11.0, taxa = 9606, protein.actions.v11.0, mode=binding, min  
362 score = 700<sup>76</sup>). Transcription factor-target relationships specific to the prefrontal cortex were  
363 included from Pearl et al<sup>20</sup>. All edge (connection) weights were normalized on a 0 to 1 scale  
364 irrespective of line of biological evidence.

365 Brain region-specific network layers were also incorporated using RNA-seq data from the  
366 Genotype-Tissue Expression (GTEx) consortium<sup>77</sup> and explainable-AI algorithms applied on the  
367 Summit supercomputer at the Oak Ridge Leadership Computing Facility (OLCF). Using iterative  
368 random forest leave-one-out prediction (iRF-LOOP<sup>78</sup>), gene-gene predictive networks were made  
369 from the prefrontal cortex (BA9) given that all omics were derived from this brain region. After  
370 computing all edges with iRF-LOOP, only high-confidence edges (edge weights > 0.05) were  
371 included in the multiplex network.

372 After compiling all network layers, the 10-layer multiplex was assembled using the  
373 “RWR\_make\_multiplex” function within the RWRtoolkit R library<sup>79</sup>. The final multiplex network  
374 contained 51,183 unique genes and 3,419,975 unique edges.

375

### 376 *Filtering opioid addiction multi-omic genes using GRIN*

377 We applied GRIN (Geneset Refinement using Interacting Networks)<sup>17</sup> to identify the most  
378 biologically interrelated opioid addiction genes and remove potential false positive genes. GRIN

379 was applied with the previously validated 10-layer multiplex network described above using the  
380 404 unique genes identified from multiple omics data using equal weights for all genes. GRIN  
381 retained 211 opioid addiction genes which were used in all subsequent analyses. Gene set  
382 enrichment for Gene Ontology (GO) Biological Processes was then tested on the 404 genes prior  
383 to GRIN as well as the GRIN retained and GRIN removed gene sets using ToppGene<sup>80</sup>. Gene set  
384 enrichments were considered significant at a threshold of FDR-corrected  $p$ -value  $< 0.05$ .

385 After retaining 211 opioid addiction genes, a set of 50 high-confidence genes were  
386 identified using two criteria. Three genes that were present in multiple omics data sets and retained  
387 by GRIN were included: *DUSP4*, *DUSP6*, and *ETV5*. Next, a subset of the 211 genes was included  
388 if each gene were associated with opioid-mediated signaling or a substance use disorder based on  
389 previously published research. This resulted in 47 additional genes in the high-confidence gene set  
390 based on a literature search from PubMed (<https://pubmed.gov>) using the following search terms:  
391 “[gene] opioid”, “[gene] addiction”, “[gene] substance use disorder.” ToppGene was then used to  
392 test for gene set enrichment of GO Biological Processes, GO Cellular Components, GO Molecular  
393 Functions, biological pathway enrichment (includes KEGG<sup>81</sup>, Reactome<sup>82</sup>, and PANTHER<sup>83</sup>  
394 pathways), and transcription factor binding sites (MSigDB<sup>84</sup>).

395

#### 396 *Shortest paths network*

397 A shortest paths network connecting all pairs of the 50 opioid addiction-associated genes  
398 was generated using the shortest paths algorithm using the R package RWRtoolkit<sup>79</sup>. The 10-layer  
399 multiplex network was merged into a single network layer, and using the shortest paths algorithm  
400 identified the shortest possible network connections among all 2500 possible gene-gene pairs.  
401 Genes who were direct neighbors with at least one other opioid addiction gene (43 out of 50 opioid

402 addiction genes) were imported into the program Cytoscape<sup>85</sup> (Version 3.9.1, Cytoscape  
403 Consortium, San Diego, CA, USA) for network visualization. For the other 7 genes (*ADRAID*,  
404 *FURIN*, *KIAA0040*, *LGALS3*, *NTN1*, *SLC1A2*, *SST*), the connections between these genes and  
405 other opioid addiction genes that were separated by one neighbor (“network-connecting genes”)  
406 were included in the Cytoscape visualization.

407

408 *Random walk with restart cross validation.*

409       Using the RWR-CV function within RWRtoolkit<sup>79</sup>, we tested the interconnectivity of our  
410 refined 50 opioid addiction gene set using random walk with restart (RWR) with 5-fold cross  
411 validation. In one cross validation fold, 10 genes were left out of our input gene set, and the other  
412 40 genes were used as seed genes for RWR. All genes in the multiplex network were ranked by  
413 RWR, with true positives counted as left-out genes that were ranked by RWR, and true negatives  
414 counted as other genes in the network. A receiver-operator characteristic (ROC) curve was  
415 calculated based on true positive rate (true positives / true positives + false negatives) and false  
416 positive rate (false positives / false positives + true negatives), which was plotted using the R  
417 package ggplot2<sup>86</sup>. The area under the curve was computed using RWRtoolkit.

418

419 *Overview and conceptual model visualizations*

420       An overview diagram of the approach used in this study was constructed using  
421 Biorender.com. Similarly, the conceptual model illustrating biological pathways among opioid  
422 addiction genes was constructed using Biorender.com.

423

424 *Identifying druggable targets involved in opioid addiction.*

425 Multi-omic opioid addiction genes were then cross-referenced with previously  
426 demonstrated gene-drug interactions. Using DrugBank<sup>87</sup>, a network of drug-gene target  
427 interactions was created using all 211 genes retained by GRIN. These drug interactions included  
428 FDA-approved, investigational, and experimental uses of drugs targeting these genes, resulting in  
429 48 gene targets and 414 total drugs. Drug-gene target interactions were visualized using Cytoscape.

### 430 **Data Availability**

431 No primary data was generated for the present study. All primary data from DNA  
432 methylation, GWAS summary statistics, H3K27ac ChIP-seq, LC/MS proteomics, and RNA-seq  
433 are from previously published manuscripts. GWAS summary statistics from the Million Veteran  
434 Program (Kember et al., 2022) are available on the NIH database of Genotypes and Phenotypes  
435 (dbGaP) under accession phs001672. GWAS summary statistics from Deak et al., 2022 are  
436 publicly available at <https://medicine.yale.edu/lab/gelernter/stats/>. GWAS summary statistics  
437 from Gaddis et al., 2022 are available under dbGaP under accession phs000454.v1.p1. We used  
438 the top 10,000 SNPs from Sanchez-Roige et al., 2021 GWAS summary statistics, which are  
439 publicly available at  
440 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562028/bin/41380\\_2021\\_1335\\_MOESM2\\_ESM.xlsx](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562028/bin/41380_2021_1335_MOESM2_ESM.xlsx). Previously published data from H3K27ac ChIP-seq is available under dbGaP accession  
441 number phs002724.v1.p1. Previously published DNA methylation data is available at GEO  
442 accession number GSE164822. Previously published LC/MS proteomics is available at the  
443 ProteomeXchange PRIDE repository under PXD025269. Previously published RNA-seq data  
444 sets are available under dbGaP accession phs002724.v1.p1, GEO accession numbers  
445 GSE221515 and GSE174409, and SRA accession number SUB9455518.

447 All activities were approved by the Oak Ridge National Laboratory Institutional Review  
448 Board. The demographics of subjects from which GWAS summary statistics were derived along  
449 with descriptions of Institutional Review Boards to approve these studies have been  
450 characterized in previous publications and all subjects provided informed consent. All  
451 postmortem brain tissue samples are exempt from human subjects research.

452

### 453 **Code Availability**

454 The GRIN software and multiplex network that was used is publicly available at  
455 [github.com/sullivanka/GRIN](https://github.com/sullivanka/GRIN). Publicly available R packages (ggplot2, tidyverse) were used for  
456 data analysis and visualization using R version 4.1.3, and ChIP-seq peaks were assigned using  
457 ChIPseeker (version 1.30.3). Additional code used to generate results are available upon request.

### 458 **Acknowledgements/Funding Sources**

459 This manuscript has been authored by UT-Battelle, LLC under Contract No. DE-AC05-  
460 00OR22725 with the U.S. Department of Energy. The United States Government retains and the  
461 publisher, by accepting the article for publication, acknowledges that the United States  
462 Government retains a non-exclusive, paid-up, irrevocable, world-wide license to publish or  
463 reproduce the published form of this manuscript, or allow others to do so, for United States  
464 Government purposes. The Department of Energy will provide public access to these results of  
465 federally sponsored research in accordance with the DOE Public Access Plan  
466 (<http://energy.gov/downloads/doe-public-access-plan>). This research used resources of the Oak  
467 Ridge Leadership Computing Facility, which is a DOE Office of Science User Facility supported

468 under Contract DE-AC05-00OR22725. This work was funded by NIH grants DA051908 (EOJ,  
469 DAJ), DA051913 (DBH, DAJ), and DA054071 (NCG, OC, BSM, SS, AP, VT, EC, EOJ, DAJ)  
470 and VA grant I01 BX004820 (ACJ, HRK) and the Veterans Integrated Service Network Mental  
471 Illness Research, Education and Clinical Center (HRK). This research is based on data from the  
472 Million Veteran Program, Office of Research and Development, Veterans Health Administration,  
473 and was supported by award # I01 BX004820. This publication does not represent the views of  
474 the Department of Veteran Affairs or the United States Government.

475

#### 476 **Author Contributions**

477 Conceptualization: DBH, EOJ, DAJ; Methodology: KAS; Software: KAS, DK, ML, MC, JIM;  
478 Formal analysis: KAS; Investigation: EOJ; Writing - Original Draft: KAS, EOJ; Writing - Review  
479 & Editing: KAS, MRG, AT, BCQ, CW, NCG, RM, OC, BSM, PCS, SS, AP, VT, EJC, RLK,  
480 HRK, ACJ, KX, BEA, DBH, EOJ, DAJ; Supervision: DBH, EOJ, DAJ; Funding acquisition:  
481 HRK, ACJ, DBH, EOJ, DAJ.


#### 482 **Competing Interests**

483 HRK is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals,  
484 Enthion Pharmaceuticals, and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the  
485 recipient of research funding and medication supplies from Alkermes for an investigator-initiated  
486 study; a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical  
487 Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm,  
488 Lundbeck, Mitsubishi, and Otsuka; and is named as an inventor on PCT patent application

489 #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018. The  
490 other authors have no disclosures to make.




## 491 Figures



492

### 493 Figure 1. Multi-omic integration of opioid addiction phenotypes.



494 Beginning with multiple data sets collected from opioid addiction (OA) cases and controls, OA  
495 genes were assembled from H3K27ac chromatin immunoprecipitation (ChIP-seq; peaks assigned  
496 to nearest gene), DNA methylation (CpG methylation site to nearest gene), genome-wide  
497 association studies (GWAS; SNP-to-gene assignment), differentially abundant proteins by LC/MS  
498 proteomics (protein-coding genes), and differential gene expression by RNA-seq. After integrating  
499 the overlapping and distinct genes identified by each omics data type, a biological multiplex  
500 network consisting of networks from multiple lines of biological evidence were constructed using  
501 data sources separate from any of the opioid addiction omics data sets. Network traversal  
502 algorithms were used to identify mechanistic connections among the multi-omic genes and identify  
503 dysregulated pathways in the dorsolateral prefrontal cortex (dlPFC). Figure made with  
504 Biorender.com.



505

506 **Figure 2. Opioid addiction genes are retained by GRIN from multiple omics types**  
 507 **and result in more Gene Ontology enrichments compared to the unfiltered gene set.**

508 **a.** Percentages of genes retained (orange) or removed (blue) by GRIN by each omics type,  
 509 including genes shared across omics types (ChIP-seq\_RNAseq, GWAS\_MTAG\_GWAS, pHiC-  
 510 VELs\_ChIPseq, and pHiC-VELs\_ChIPseq\_RNAseq). **b.** From the 404 original opioid addiction  
 511 genes (Pre-GRIN), 159 GO Biological Process terms were significantly enriched. The 211 genes  
 512 retained by GRIN (Post-GRIN) were enriched for 96 of the same GO Biological Processes but  
 513 were uniquely enriched for 197 additional terms. Only 7 terms were significantly enriched in the  
 514 set of 404 genes prior to GRIN that were not significantly enriched in the post-GRIN set of 211  
 515 genes.




516

517 **Figure 3. Multi-omic opioid addiction genes are tightly interconnected as**  
 518 **demonstrated by network biology.**

519 **a.** Network visualization of the shortest pathways between all pairs of 50 opioid addiction (OA)-  
 520 associated genes from GWAS and dIPFC omics. 43 genes were directly connected to at least one  
 521 other gene by the networks (Direct Neighbor OA genes), and only 127 additional genes (Network-  
 522 Connecting Genes) were necessary to connect the other 7 genes (One Neighbor OA Genes) from  
 523 10 network layers. Notably, three Network-Connecting genes (*SERPINB1*, *SORCS1*, and *SORL1*)


524 were members of the larger 211 GRIN-retained opioid addiction gene set. Gene Legend: indicates  
525 gene color from which omics data type or if it is a Network-Connecting Gene; Network  
526 Connections legend indicates network layer used to connect gene pairs. **b.** Using Random Walk  
527 with Restart to explore the biological networks starting from 50 OA-associated genes, 5-fold cross  
528 validation exhibits high recall based upon a mean area under receiver-operator characteristic curve  
529 (AUROC) value of 0.94.



530

531 **Figure 4. Conceptual model of opioid addiction pathways implicated by multi-omic**  
 532 **integration.**

533 Conceptual model of 45 opioid addiction genes identified via multiple omics data types and 26  
 534 additional genes, proteins, or molecules in associated pathways. The mu-opioid receptor (*OPRM1*)  
 535 and *GABBR2* receptor inhibit downstream adenylyl cyclase/protein kinase A (PKA) signaling.  
 536 PKA can phosphorylate ERK1 which is bound by the scaffolding protein PEA-15, and ERK can  
 537 also be activated by upstream netrin (*NTN1*) and BDNF signaling molecules that were implicated  
 538 in opioid addiction (*BDNF*, *NTRK2*, *RASGRF1*). *DUSP2*, *DUSP4*, *DUSP6*, *DUSP10*, and *PPP6C*  
 539 all function as ERK phosphatases and *PDE4B* can reduce PKA activation, while Akt signaling  
 540 (implicated by *PIK3RA* and *GSK3B*) and ERK signaling can activate *NPAS4* and *CREB5* to  
 541 activate transcription of *NTN1* (identified by DNA hypermethylation) and synaptic plasticity and  
 542 immediate early genes (*ARC*, *BDNF*, *EGR1*, *EGR2*, *EGR4*, *ETS1*, *ETV5*, *FOS*, *MYC*, *NPAS4*, *SST*).  
 543 ERK can also activate the transcription factor *RORA* to promote transcription of *ASTN2* and  
 544 galectin-3 (*LGALS3*), which is important in microglial inflammatory processes. *OPRM1*  
 545 (chaperoned to the cell membrane by *RTP4*) and *FURIN* share a common scaffolding protein  
 546 (filamin A; *FLNA*) with the glutamatergic kainate receptor subunit *GRIK3*, and *SLC1A2* is an  
 547 important glutamate transporter in astrocytes. Additional potassium and calcium channel subunits  
 548 (*ABCC8*, *KCNMA1*, *KCNN1*) were implicated along with multiple ionotropic GABA<sub>A</sub> receptor  
 549 subunits (*GABRE*, *GABRG3*) and cell adhesion molecules (*NCAM1* and *NRXN3*). Color of gene  
 550 text indicates which opioid addiction omics data set the gene originated from, and shading of the  
 551 gene indicates the log<sub>2</sub>FC of expression or histone acetylation state (not applicable for pc Hi-C  
 552 VELS or GWAS genes). *NTN1* was hypermethylated by a mean difference of 0.29 rather than a  
 553 log<sub>2</sub>FC difference in methylation state. Gray text genes indicate genes or molecules involved in  
 554 pathways but were not implicated by an omics study.



555 **Figure 5. Drug-gene target network includes current opioid treatments and putative**  
 556 **candidate drugs for treatment repurposing.**

557 A network of 414 drugs and 48 target genes (orange) implicated in multi-omic opioid addiction  
 558 studies. Current opioid addiction/opioid use disorder (OUD) treatments (light yellow-green)  
 559 targeting the  $\mu$ -opioid receptor (*OPRM1*) include buprenorphine, methadone, and naltrexone, as  
 560 well as nalmefene and naloxone to prevent overdose. In addition to nalmefene and naltrexone  
 561 which is used to treat OUD and alcohol use disorder (AUD), four approved or experimental alcohol  
 562 use disorder treatments (light green) were present in the network: acamprosate (targeting *GABRE*  
 563 and *GABRG3*), baclofen (targeting *GABBR2*), ibudilast (targeting *PDE4B*), and topiramate  
 564 (*CACNB2*, *GRIK3*, and *SCN8A*). Drugs with known psychiatric effects (teal) targeting opioid  
 565 addiction genes include spironolactone (also investigated for AUD), antidepressants (e.g.,  
 566 amitriptyline, amoxipine, and esketamine, targeting 6 unique genes). Some drugs in the network  
 567 with known misuse potential (dark blue) include antipsychotic drugs (e.g., aripiprazole,  
 568 quetiapine) and many benzodiazepines that act as anxiolytics (e.g., alprazolam, lorazepam).  
 569 Multiple ion channel receptor subunits (15 total) are also known drug targets, and 9 genes are  
 570 known to be targeted by fostamatinib. Other drugs with yet unknown psychiatric effects targeting  
 571 opioid addiction genes are shown in light blue, along with a number of opioids (gray). This drug-  
 572 gene target network may guide additional hypotheses and follow up experiments to test the  
 573 efficacy of these drugs in combating opioid addiction processes.

574 **References**

- 575 1. Unodc. World drug report 2021-drug market trends: cannabis & opioids. (2021).
- 576 2. Substance Abuse and Mental Health Services Administration. Key substance use and mental  
577 health indicators in the United States: Results from the 2020 national survey on drug use and  
578 health. (*HHS Publication No. PEP21-07-01-003, NSDUH Series H-56*). (2021).
- 579 3. Spencer, M., Miniño, A. & Warner, M. *Drug overdose deaths in the United States, 2001–*  
580 *2021*. <https://stacks.cdc.gov/view/cdc/122556> (2022) doi:10.15620/cdc:122556.
- 581 4. Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts.  
582 *National Center for Health Statistics*. (2023).
- 583 5. U.S. Department of Health and Human Services. HHS By The Numbers: Combating the  
584 Opioids Crisis. (2019).
- 585 6. Sanchez-Roige, S. *et al.* Genome-wide association study of problematic opioid prescription  
586 use in 132,113 23andMe research participants of European ancestry. *Mol. Psychiatry* **26**,  
587 6209–6217 (2021).
- 588 7. Deak, J. D. *et al.* Genome-wide association study in individuals of European and African  
589 ancestry and multi-trait analysis of opioid use disorder identifies 19 independent genome-  
590 wide significant risk loci. *Mol. Psychiatry* (2022) doi:10.1038/s41380-022-01709-1.
- 591 8. Kember, R. L. *et al.* Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci  
592 with predominant effects in brain regions associated with addiction. *Nat. Neurosci.* (2022)  
593 doi:10.1038/s41593-022-01160-z.
- 594 9. Gaddis, N. *et al.* Multi-trait genome-wide association study of opioid addiction: OPRM1  
595 and beyond. *Sci. Rep.* **12**, 16873 (2022).
- 596 10. Zhou, H. *et al.* Association of OPRM1 Functional Coding Variant with Opioid Use  
597 Disorder: A Genome-Wide Association Study. *JAMA Psychiatry* **77**, 1072–1080 (2020).

- 598 11. Corradin, O. *et al.* Convergence of case-specific epigenetic alterations identify a confluence  
599 of genetic vulnerabilities tied to opioid overdose. *Mol. Psychiatry* **27**, 2158–2170 (2022).
- 600 12. Mendez, E. F. *et al.* Angiogenic gene networks are dysregulated in opioid use disorder:  
601 evidence from multi-omics and imaging of postmortem human brain. *Mol. Psychiatry*  
602 (2021) doi:10.1038/s41380-021-01259-y.
- 603 13. Seney, M. L. *et al.* Transcriptional Alterations in Dorsolateral Prefrontal Cortex and Nucleus  
604 Accumbens Implicate Neuroinflammation and Synaptic Remodeling in Opioid Use  
605 Disorder. *Biol. Psychiatry* **90**, 550–562 (2021).
- 606 14. Sosnowski, D. W. *et al.* Differential expression of NPAS4 in the dorsolateral prefrontal  
607 cortex following opioid overdose. *Drug and Alcohol Dependence Reports* **3**, 100040 (2022).
- 608 15. Shu, C. *et al.* Epigenome-wide study of brain DNA methylation following acute opioid  
609 intoxication. *Drug Alcohol Depend.* **221**, 1–7 (2021).
- 610 16. Carter, J. Quach, B., Willis, C., Hancock, D., Montalvo-Ortiz, J., Logan, R., Walss-Bass, C.,  
611 Maher, B., Johnson, E., PGC-SUD Epigenetics Working Group. Identifying novel gene  
612 dysregulation associated with opioid overdose death: A meta-analysis of differential gene  
613 expression in human prefrontal cortex; Poster Presentation: PB1478. American Society of  
614 Human Genetics, Los Angeles, CA, Oct 2022.
- 615 17. Sullivan, K. A. *et al.* Digging deeper into GWAS signal using GRIN implicates additional  
616 genes contributing to suicidal behavior. *bioRxiv* (2022) doi:10.1101/2022.04.20.22273895.
- 617 18. Harris, M. A. *et al.* The Gene Ontology (GO) database and informatics resource. *Nucleic*  
618 *Acids Res.* **32**, D258–61 (2004).
- 619 19. Funahashi, Y. *et al.* Phosphorylation of Npas4 by MAPK Regulates Reward-Related Gene  
620 Expression and Behaviors. *Cell Rep.* **29**, 3235–3252.e9 (2019).



- 621 20. Pearl, J. R. *et al.* Genome-Scale Transcriptional Regulatory Network Models of Psychiatric  
622 and Neurodegenerative Disorders. *Cell Systems* **8**, 122–135.e7 (2019).
- 623 21. Onoprishvili, I. *et al.* Interaction between the mu opioid receptor and filamin A is involved  
624 in receptor regulation and trafficking. *Mol. Pharmacol.* **64**, 1092–1100 (2003).
- 625 22. Liu, G. *et al.* Cytoskeletal protein ABP-280 directs the intracellular trafficking of furin and  
626 modulates proprotein processing in the endocytic pathway. *J. Cell Biol.* **139**, 1719–1733  
627 (1997).
- 628 23. Hwang, S. *et al.* HumanNet v2: human gene networks for disease research. *Nucleic Acids*  
629 *Res.* **47**, D573–D580 (2019).
- 630 24. Schachner, M. Neural recognition molecules and synaptic plasticity. *Curr. Opin. Cell Biol.*  
631 **9**, 627–634 (1997).
- 632 25. Dai, J., Liakath-Ali, K., Golf, S. R. & Südhof, T. C. Distinct neurexin-cerebellin complexes  
633 control AMPA- and NMDA-receptor responses in a circuit-dependent manner. *Elife* **11**,  
634 (2022).
- 635 26. Liu, Y. *et al.* Galectin-3 regulates microglial activation and promotes inflammation through  
636 TLR4/MyD88/NF- $\kappa$ B in experimental autoimmune uveitis. *Clin. Immunol.* **236**, 108939  
637 (2022).
- 638 27. Carpenter, J. E., LaPrad, D., Dayo, Y., DeGrote, S. & Williamson, K. An Overview of  
639 Pharmacotherapy Options for Alcohol Use Disorder. *Fed. Pract.* **35**, 48–58 (2018).
- 640 28. Grodin, E. N. *et al.* Ibudilast, a neuroimmune modulator, reduces heavy drinking and  
641 alcohol cue-elicited neural activation: a randomized trial. *Transl. Psychiatry* **11**, 355 (2021).
- 642 29. Kranzler, H. R. *et al.* Post-treatment effects of topiramate on alcohol-related outcomes: A  
643 combined analysis of two placebo-controlled trials. *Addict. Biol.* **27**, e13130 (2022).

- 644 30. Farokhnia, M. *et al.* Spironolactone as a potential new pharmacotherapy for alcohol use  
645 disorder: convergent evidence from rodent and human studies. *Mol. Psychiatry* **27**, 4642–  
646 4652 (2022).
- 647 31. Jha, M. K. *et al.* Intranasal esketamine effectively treats treatment-resistant depression in  
648 adults regardless of baseline irritability. *J. Affect. Disord.* **321**, 153–160 (2023).
- 649 32. Kishi, T. *et al.* Antidepressants for the treatment of adults with major depressive disorder in  
650 the maintenance phase: a systematic review and network meta-analysis. *Mol. Psychiatry*  
651 (2022) doi:10.1038/s41380-022-01824-z.
- 652 33. Merino, D. *et al.* Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric  
653 Population: A Real-World Disproportionality Analysis. *Biomedicines* **10**, (2022).
- 654 34. Ferreira, R. C. M. *et al.* Peripheral Antinociception Induced by Aripiprazole Is Mediated by  
655 the Opioid System. *Biomed Res. Int.* **2017**, 8109205 (2017).
- 656 35. Dorman, A., Talbot, D., Byrne, P. & O'Connor, J. Misuse of dothiepin. *BMJ* **311**, 1502  
657 (1995).
- 658 36. Klein, L., Bangh, S. & Cole, J. B. Intentional Recreational Abuse of Quetiapine Compared  
659 to Other Second-generation Antipsychotics. *West. J. Emerg. Med.* **18**, 243–250 (2017).
- 660 37. Ait-Daoud, N., Hamby, A. S., Sharma, S. & Blevins, D. A Review of Alprazolam Use,  
661 Misuse, and Withdrawal. *J. Addict. Med.* **12**, 4–10 (2018).
- 662 38. Garretty, D. J., Wolff, K., Hay, A. W. & Raistrick, D. Benzodiazepine misuse by drug  
663 addicts. *Ann. Clin. Biochem.* **34** ( Pt 1), 68–73 (1997).
- 664 39. Liu, S. *et al.* Brain responses to drug cues predict craving changes in abstinent heroin users:  
665 A preliminary study. *Neuroimage* **237**, 118169 (2021).
- 666 40. Wang, L. *et al.* Altered brain intrinsic functional hubs and connectivity associated with

- 667 relapse risk in heroin dependents undergoing methadone maintenance treatment: A resting-  
668 state fMRI study. *Drug Alcohol Depend.* **219**, 108503 (2021).
- 669 41. Huhn, A. S. *et al.* Prefrontal cortex response to drug cues, craving, and current depressive  
670 symptoms are associated with treatment outcomes in methadone-maintained patients.  
671 *Neuropsychopharmacology* **44**, 826–833 (2019).
- 672 42. Doherty, J. M., Cooke, B. M. & Frantz, K. J. A role for the prefrontal cortex in heroin-  
673 seeking after forced abstinence by adult male rats but not adolescents.  
674 *Neuropsychopharmacology* **38**, 446–454 (2013).
- 675 43. Kuntz, K. L., Patel, K. M., Grigson, P. S., Freeman, W. M. & Vrana, K. E. Heroin self-  
676 administration: II. CNS gene expression following withdrawal and cue-induced drug-  
677 seeking behavior. *Pharmacol. Biochem. Behav.* **90**, 349–356 (2008).
- 678 44. Koya, E. *et al.* Enhanced cortical and accumbal molecular reactivity associated with  
679 conditioned heroin, but not sucrose-seeking behaviour. *J. Neurochem.* **98**, 905–915 (2006).
- 680 45. Flaisher-Grinberg, S., Persaud, S. D., Loh, H. H. & Wei, L.-N. Stress-induced epigenetic  
681 regulation of  $\kappa$ -opioid receptor gene involves transcription factor c-Myc. *Proc. Natl. Acad.*  
682 *Sci. U. S. A.* **109**, 9167–9172 (2012).
- 683 46. Park, S. W., Li, J., Loh, H. H. & Wei, L.-N. A novel signaling pathway of nitric oxide on  
684 transcriptional regulation of mouse kappa opioid receptor gene. *J. Neurosci.* **22**, 7941–7947  
685 (2002).
- 686 47. Tsai, N.-P., Bi, J., Loh, H. H. & Wei, L.-N. Netrin-1 signaling regulates de novo protein  
687 synthesis of kappa opioid receptor by facilitating polysomal partition of its mRNA. *J.*  
688 *Neurosci.* **26**, 9743–9749 (2006).
- 689 48. Décaillot, F. M., Rozenfeld, R., Gupta, A. & Devi, L. A. Cell surface targeting of mu-delta

- 690 opioid receptor heterodimers by RTP4. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 16045–16050  
691 (2008).
- 692 49. Fujita, W. *et al.* Regulation of an Opioid Receptor Chaperone Protein, RTP4, by Morphine.  
693 *Mol. Pharmacol.* **95**, 11–19 (2019).
- 694 50. Bagherpasand, N. *et al.* Effect of topiramate on morphine-induced conditioned place  
695 preference (Cp) in rats: Role of erk and creb proteins in hippocampus and cerebral cortex.  
696 *Iranian Journal of Pharmaceutical Research* **18**, 2000–2010 (2019).
- 697 51. Ramos-Miguel, A., Esteban, S. & García-Sevilla, J. A. The time course of unconditioned  
698 morphine-induced psychomotor sensitization mirrors the phosphorylation of FADD and  
699 MEK/ERK in rat striatum: role of PEA-15 as a FADD-ERK binding partner in striatal  
700 plasticity. *Eur. Neuropsychopharmacol.* **20**, 49–64 (2010).
- 701 52. Koo, J. W. *et al.* Epigenetic basis of opiate suppression of Bdnf gene expression in the  
702 ventral tegmental area. *Nat. Neurosci.* **18**, 415–422 (2015).
- 703 53. Dai, Q. *et al.* Whole Transcriptome Sequencing of Peripheral Blood Shows That  
704 Immunity/GnRH/PI3K-Akt Pathways Are Associated With Opioid Use Disorder. *Front.*  
705 *Psychiatry* **13**, 893303 (2022).
- 706 54. Fiorentino, A., Sharp, S. I. & McQuillin, A. Association of rare variation in the glutamate  
707 receptor gene SLC1A2 with susceptibility to bipolar disorder and schizophrenia. *Eur. J.*  
708 *Hum. Genet.* **23**, 1200–1206 (2015).
- 709 55. O’Donnell, A., Odrowaz, Z. & Sharrocks, A. D. Immediate-early gene activation by the  
710 MAPK pathways: what do and don’t we know? *Biochem. Soc. Trans.* **40**, 58–66 (2012).
- 711 56. Heroux, N. A. *et al.* Differential expression of the immediate early genes c-Fos, Arc, Egr-1,  
712 and Npas4 during long-term memory formation in the context preexposure facilitation effect

- 713 (CPFE). *Neurobiol. Learn. Mem.* **147**, 128–138 (2018).
- 714 57. Gerhauser, I., Alldinger, S., Ulrich, R. & Baumgärtner, W. Spatio-temporal expression of  
715 immediate early genes in the central nervous system of SJL/J mice. *Int. J. Dev. Neurosci.*  
716 **23**, 637–649 (2005).
- 717 58. Tran, D. D. H. *et al.* Transcriptional regulation of immediate-early gene response by  
718 THOC5, a member of mRNA export complex, contributes to the M-CSF-induced  
719 macrophage differentiation. *Cell Death Dis.* **4**, e879–e879 (2013).
- 720 59. Gao, P., Limpens, J. H. W., Spijker, S., Vanderschuren, L. J. M. J. & Voorn, P. Stable  
721 immediate early gene expression patterns in medial prefrontal cortex and striatum after long-  
722 term cocaine self-administration. *Addict. Biol.* **22**, 354–368 (2017).
- 723 60. Hayashi, T., Ko, J. H., Strafella, A. P. & Dagher, A. Dorsolateral prefrontal and  
724 orbitofrontal cortex interactions during self-control of cigarette craving. *Proc. Natl. Acad.*  
725 *Sci. U. S. A.* **110**, 4422–4427 (2013).
- 726 61. Huhn, A. S. *et al.* Increased neural activity in the right dorsolateral prefrontal cortex during  
727 a risky decision-making task is associated with cocaine use in methadone-maintained  
728 patients. *Drug Alcohol Depend.* **205**, 107650 (2019).
- 729 62. Eskandari, Z. *et al.* A sham-controlled clinical trial to examine the effect of bilateral tDCS  
730 on craving, TNF- $\alpha$  and IL-6 expression levels, and impulsivity of males with opioid use  
731 disorder. *J. Addict. Dis.* **39**, 347–356 (2021).
- 732 63. Tsai, T.-Y. *et al.* Add-on repetitive transcranial magnetic stimulation in patients with opioid  
733 use disorder undergoing methadone maintenance therapy. *Am. J. Drug Alcohol Abuse* **47**,  
734 330–343 (2021).
- 735 64. Cabrera-Mendoza, B. *et al.* Within subject cross-tissue analyzes of epigenetic clocks in

- 736 substance use disorder postmortem brain and blood. *Am. J. Med. Genet. B Neuropsychiatr.*  
737 *Genet.* (2022) doi:10.1002/ajmg.b.32920.
- 738 65. Montalvo-Ortiz, J. L., Cheng, Z., Kranzler, H. R., Zhang, H. & Gelernter, J. Genomewide  
739 Study of Epigenetic Biomarkers of Opioid Dependence in European- American Women.  
740 *Sci. Rep.* **9**, 4660 (2019).
- 741 66. Saad, M. H. *et al.* Differentially expressed gene networks, biomarkers, long noncoding  
742 RNAs, and shared responses with cocaine identified in the midbrains of human opioid  
743 abusers. *Sci. Rep.* **9**, 1534 (2019).
- 744 67. Albertson, D. N., Schmidt, C. J., Kapatos, G. & Bannon, M. J. Distinctive profiles of gene  
745 expression in the human nucleus accumbens associated with cocaine and heroin abuse.  
746 *Neuropsychopharmacology* **31**, 2304–2312 (2006).
- 747 68. Kozlenkov, A. *et al.* DNA Methylation Profiling of Human Prefrontal Cortex Neurons in  
748 Heroin Users Shows Significant Difference between Genomic Contexts of Hyper- and  
749 Hypomethylation and a Younger Epigenetic Age. *Genes* **8**, (2017).
- 750 69. Egervari, G. *et al.* Chromatin accessibility mapping of the striatum identifies tyrosine kinase  
751 FYN as a therapeutic target for heroin use disorder. *Nat. Commun.* **11**, 4634 (2020).
- 752 70. Egervari, G. *et al.* Striatal H3K27 Acetylation Linked to Glutamatergic Gene Dysregulation  
753 in Human Heroin Abusers Holds Promise as Therapeutic Target. *Biol. Psychiatry* **81**, 585–  
754 594 (2017).
- 755 71. Coffa, D. & Snyder, H. Opioid Use Disorder: Medical Treatment Options. *Am. Fam.*  
756 *Physician* **100**, 416–425 (2019).
- 757 72. Zullino, D. F. *et al.* Topiramate in opiate withdrawal- comparison with clonidine and with  
758 carbamazepine/mianserin. *Subst. Abus.* **25**, 27–33 (2004).

- 759 73. Rush, C. R. *et al.* Topiramate-phentermine combinations reduce cocaine self-administration  
760 in humans. *Drug Alcohol Depend.* **218**, 108413 (2021).
- 761 74. Yu, G., Wang, L.-G. & He, Q.-Y. ChIPseeker: an R/Bioconductor package for ChIP peak  
762 annotation, comparison and visualization. *Bioinformatics* **31**, 2382–2383 (2015).
- 763 75. McLean, C. Y. *et al.* GREAT improves functional interpretation of cis-regulatory regions.  
764 *Nat. Biotechnol.* **28**, 495–501 (2010).
- 765 76. Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with increased  
766 coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic  
767 Acids Res.* **47**, D607–D613 (2019).
- 768 77. Melé, M. *et al.* The human transcriptome across tissues and individuals. *Science* **348**, 660–  
769 665 (2015).
- 770 78. Cliff, A. *et al.* A High-Performance Computing Implementation of Iterative Random Forest  
771 for the Creation of Predictive Expression Networks. *Genes* **10**, (2019).
- 772 79. Kainer, D., Lane, M., Sullivan, K., Cashman, M. & Miller, J. *dkainer/RWRtoolkit*. (Oak  
773 Ridge National Laboratory (ORNL), Oak Ridge, TN (United States), 2022).  
774 doi:10.11578/DC.20220607.1.
- 775 80. Chen, J., Bardes, E. E., Aronow, B. J. & Jegga, A. G. ToppGene Suite for gene list  
776 enrichment analysis and candidate gene prioritization. *Nucleic Acids Res.* **37**, W305–11  
777 (2009).
- 778 81. Ogata, H., Goto, S., Fujibuchi, W. & Kanehisa, M. Computation with the KEGG pathway  
779 database. *Biosystems.* **47**, 119–128 (1998).
- 780 82. Gillespie, M. *et al.* The reactome pathway knowledgebase 2022. *Nucleic Acids Res.* **50**,  
781 D687–D692 (2022).

- 782 83. Mi, H. & Thomas, P. PANTHER pathway: an ontology-based pathway database coupled  
783 with data analysis tools. *Methods Mol. Biol.* **563**, 123–140 (2009).
- 784 84. Liberzon, A. *et al.* Molecular signatures database (MSigDB) 3.0. *Bioinformatics* **27**, 1739–  
785 1740 (2011).
- 786 85. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular  
787 interaction networks. *Genome Res.* **13**, 2498–2504 (2003).
- 788 86. Wickham, H. *ggplot2: elegant graphics for data analysis* Springer-Verlag New York; 2009.  
789 Preprint at (2016).
- 790 87. Wishart, D. S. *et al.* DrugBank 5.0: a major update to the DrugBank database for 2018.  
791 *Nucleic Acids Res.* **46**, D1074–D1082 (2018).